- Bristol Myers Squibb has selected Houston, Texas, for a new $2.3 billion manufacturing campus, which is expected to create nearly 500 jobs.
- Governor Greg Abbott announced that the campus will be located at Generation Park in Harris County.
- The state has extended a $4.89 million Texas Enterprise Fund grant to Bristol Myers Squibb and qualified the project under JETI.
- Bristol Myers Squibb expects to create approximately 2,000 construction and indirect jobs between 2027–2030 as the facility is built.
- This investment is part of Bristol Myers Squibb's $40 billion commitment to the United States, aimed at enhancing domestic manufacturing capabilities.
- Christopher Boerner, Board Chair and CEO of Bristol Myers Squibb, stated that this investment reflects confidence in America's leadership in biopharmaceutical innovation.
- The new campus will be a modular, multi-modal facility designed for flexibility and long-term growth, allowing for the production of various types of medicines.
Bristol Myers Squibb (BMS) has announced a significant investment of $2.3 billion to establish a new manufacturing campus in Houston, Texas, which is expected to create nearly 500 skilled jobs. This initiative is part of BMS's broader $40 billion commitment to the U.S. over five years, aimed at enhancing domestic manufacturing capabilities and supporting the development of next-generation medicines.156
The new facility, located at Generation Park, will be a modular, multi-modal campus designed for flexibility and long-term growth. It will enable BMS to manufacture various types of medicines, including small molecules, biologics, and antibody-drug conjugates, across multiple disease areas. The campus is projected to employ nearly 500 people initially, with roles in operations, production, maintenance, quality control, and administration.28
Texas Governor Greg Abbott emphasized the importance of this investment, stating, “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce.” The project is also expected to generate approximately 2,000 construction and indirect jobs between 2027 and 2030, further supporting the local economy.
BMS's decision to select Houston followed a competitive evaluation of multiple markets, with key factors including the local workforce's strength in life sciences and the favorable business climate in Texas. Christopher Boerner, BMS's Board Chair and CEO, stated, “This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation.”7
“The campus at Generation Park will be modular and multi-modal, capable of producing small molecules, biologics, and antibody-drug conjugates. Texas extended a $4.89 million Enterprise Fund grant, and BMS expects about 2,000 construction jobs between 2027–2030.”
KHOU
